EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Search
Boehringer Ingelheim opens Health Management Centre in China
Boehringer Ingelheim opens Health Management Centre in China The new Health Management Centre integrates animal disease and health diagnostics as well as monitoring tools The centre further strengthens the company’s ability to provide services along the f
Our Biotech Story | Bioxcellence | Boehringer Ingelheim
Discover our pioneering history & leadership in biotechnology, driving innovation in biopharmaceutical manufacturing & breakthrough therapies.
Scleroderma
Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs
founding-member-of-QUTAC
Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
Genomic Lens Linking Worlds in DNA
Adding a new dimension to drug discovery with the help of data science and DNA
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.